Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company is engaged in developing opioid antagonist treatments for substance use, addictive and eating disorders. The Company focuses on developing a treatment for reverse opioid overdoses, a treatment for overweight and obese patients with binge eating disorder, and a treatment for cocaine use disorder (CocUD). The Company is developing a treatment for reversing opioid overdoses in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The Company is also developing a treatment for binge eating disorder derived from the Sinclair Method. The Company also has completed a Phase II clinical trial to treat binge eating disorder. The Company's product, NARCAN Nasal Spray, contains naloxone hydrochloride. NARCAN Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.